Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Abatacept in Treating Adults With Mild Relapsing Wegener`s Granulomatosis

Study:

A Multi-Center, Open-label Pilot Study of Abatacept (CTLA4-Ig) in the Treatment of Mild Relapsing Wegener`s Granulomatosis

Rationale:

n/a

Purpose:

Wegener`s granulomatosis (WG) is a rare disease that causes inflammation of blood vessels, or vasculitis. It may involve many different parts of the body, but typically affects the upper and lower respiratory tract and kidneys. The purpose of this study was to determine the safety and effectiveness of the medication abatacept in treating adults with mild relapsing WG.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Wegener`s Granulomatosis Drug: Abatacept Phase 1/Phase 2

Verified by University of Pennsylvania September, 2013

Sponsored by: University of Pennsylvania
Information provided by: University of Pennsylvania
ClinicalTrials.gov identifier: NCT00468208

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Carol A. Langford, MD, MHS., Principal Investigator
Peter A. Merkel, MD, MPH., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site